Ozempic Shows Remarkable Anti-Aging Effects in Clinical Trial

A clinical trial has revealed that the diabetes drug Ozempic (semaglutide) demonstrates significant anti-aging effects. In a 32-week study involving patients with HIV-associated lipohypertrophy, participants receiving Ozempic became an average of 3.1 years biologically younger. Researchers used epigenetic clocks to measure biological age, finding that Ozempic slowed and even reversed biological aging, particularly in the inflammatory system and brain. The anti-aging properties are believed to stem from Ozempic's impact on fat distribution and metabolic health. While the study focused on a specific population, the findings suggest potential benefits for a broader population. Further research is needed to confirm these effects in larger, more diverse groups.